

REMARKS


In response to the Restriction Requirement dated July 26, 2005, Applicants elect the invention of Group 1, claims 1-7, drawn to a method of treating nephritis using an antibody that binds to platelet derived growth factor-DD (PDGF-DD), without traverse. In response to the species election regarding a method of treating a specific autoimmune disease, Applicants further elect the mesangial proliferative nephritis.

Upon entry of the present amendment, claims 1-7 and 22-33 are pending. Claims 8-21 have been cancelled without prejudice or disclaimer. Applicants reserve the right to prosecute that subject matter, as well as the originally presented claims, in continuing applications. Claims 1 and 3 have been amended, and claims 22-33 have been added. Support for the amendments presented herein is found throughout the specification and claims as originally filed. For example, support for the antibodies recited by amended claim 1 and new claims 22-26 and 33 is found at least at page 36, paragraph [0113] and at page 37, paragraph [0115]. Support for new dependent claims 27-32 is found in claims 2-7 as originally filed. Accordingly, no new matter has been added by the claim amendments presented herein.

CONCLUSION

On the basis of the foregoing amendment and remarks, Applicants respectfully submit, that the pending claims are in condition for allowance. If there are any questions regarding this amendment and/or these remarks, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, Reg. No. 38,384
Attorney for Applicants
c/o MINTZ, LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No.: 55111